Neuropathy and fatal hepatitis in a patient receiving amiodarone

45Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Muscle weakness, neuropathy, and transient rises in hepatic enzyme activity have been reported with the use of the antiarrhythmic agent amiodarone. A 68 year old teetotaller with normal liver function was given amiodarone for resistant supraventricular arrhythmias. He presented 19 months later with vomiting, muscle weakness and wasting, sensory neuropathy, and hepatomegaly. Liver biopsy showed fibrosis and the presence of hyaline. The amiodarone was withdrawn. Three months later he developed ascites. Oesophageal varices were found and he later died. The liver showed micronodular cirrhosis. The large volume of distribution and long half life of amiodarone may explain the persistence of toxicity, which may have been aggravated by simultaneously administered doxepin in this case. Amiodarone should be withdrawn if abnormal liver function or neuropathy develops.

Cite

CITATION STYLE

APA

Lim, P. K., Trewby, P. N., Storey, G. C. A., & Holt, D. W. (1984). Neuropathy and fatal hepatitis in a patient receiving amiodarone. British Medical Journal, 288(6431), 1638–1639. https://doi.org/10.1136/bmj.288.6431.1638

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free